A detailed history of Martin & CO Inc transactions in Amgen Inc stock. As of the latest transaction made, Martin & CO Inc holds 4,963 shares of AMGN stock, worth $1.55 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
4,963
Previous 5,120 3.07%
Holding current value
$1.55 Million
Previous $1.47 Million 4.27%
% of portfolio
0.37%
Previous 0.38%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$268.87 - $324.56 $42,212 - $50,955
-157 Reduced 3.07%
4,963 $1.41 Million
Q4 2023

Feb 13, 2024

SELL
$255.7 - $288.46 $57,532 - $64,903
-225 Reduced 4.21%
5,120 $1.47 Million
Q3 2023

Nov 02, 2023

SELL
$218.65 - $271.46 $5,466 - $6,786
-25 Reduced 0.47%
5,345 $1.44 Million
Q2 2023

Aug 10, 2023

SELL
$214.27 - $253.37 $54,424 - $64,355
-254 Reduced 4.52%
5,370 $1.19 Million
Q1 2023

May 09, 2023

SELL
$225.79 - $275.2 $62,318 - $75,955
-276 Reduced 4.68%
5,624 $1.36 Million
Q4 2022

Feb 03, 2023

BUY
$229.03 - $291.01 $139,250 - $176,934
608 Added 11.49%
5,900 $1.55 Million
Q3 2022

Oct 26, 2022

BUY
$224.46 - $253.15 $16,610 - $18,733
74 Added 1.42%
5,292 $1.19 Million
Q2 2022

Aug 11, 2022

SELL
$230.71 - $256.74 $2,307 - $2,567
-10 Reduced 0.19%
5,218 $1.27 Million
Q1 2022

May 04, 2022

SELL
$219.27 - $242.57 $81,568 - $90,236
-372 Reduced 6.64%
5,228 $1.26 Million
Q4 2021

Feb 01, 2022

SELL
$198.88 - $227.6 $12,131 - $13,883
-61 Reduced 1.08%
5,600 $1.26 Million
Q3 2021

Nov 02, 2021

BUY
$212.27 - $248.7 $104,012 - $121,863
490 Added 9.48%
5,661 $1.2 Million
Q2 2021

Jul 28, 2021

SELL
$233.58 - $259.14 $55,124 - $61,157
-236 Reduced 4.36%
5,171 $1.26 Million
Q1 2021

May 14, 2021

SELL
$221.91 - $258.6 $36,393 - $42,410
-164 Reduced 2.94%
5,407 $1.35 Million
Q4 2020

Feb 12, 2021

BUY
$216.38 - $257.67 $5,409 - $6,441
25 Added 0.45%
5,571 $1.28 Million
Q3 2020

Nov 12, 2020

SELL
$234.65 - $260.95 $21,118 - $23,485
-90 Reduced 1.6%
5,546 $1.41 Million
Q2 2020

Aug 19, 2020

SELL
$197.81 - $242.74 $2,967 - $3,641
-15 Reduced 0.27%
5,636 $1.33 Million
Q1 2020

May 13, 2020

BUY
$182.24 - $241.7 $14,943 - $19,819
82 Added 1.47%
5,651 $1.15 Million
Q4 2019

Feb 13, 2020

SELL
$189.21 - $243.2 $4,730 - $6,080
-25 Reduced 0.45%
5,569 $1.34 Million
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $4,352 - $5,215
-25 Reduced 0.44%
5,594 $1.08 Million
Q2 2019

Aug 15, 2019

SELL
$166.7 - $195.41 $20,837 - $24,426
-125 Reduced 2.18%
5,619 $1.04 Million
Q1 2019

May 15, 2019

SELL
$180.87 - $203.88 $83,200 - $93,784
-460 Reduced 7.41%
5,744 $1.09 Million
Q4 2018

Feb 13, 2019

SELL
$178.4 - $208.25 $9,812 - $11,453
-55 Reduced 0.88%
6,204 $1.21 Million
Q3 2018

Nov 15, 2018

SELL
$185.29 - $208.89 $22,234 - $25,066
-120 Reduced 1.88%
6,259 $1.3 Million
Q2 2018

Aug 15, 2018

SELL
$166.05 - $186.51 $943,662 - $1.06 Million
-5,683 Reduced 47.11%
6,379 $1.18 Million
Q1 2018

May 15, 2018

SELL
$169.43 - $198.0 $18,637 - $21,780
-110 Reduced 0.9%
12,062 $2.06 Million
Q4 2017

Feb 15, 2018

SELL
$168.79 - $188.59 $14,347 - $16,030
-85 Reduced 0.69%
12,172 $2.12 Million
Q3 2017

Nov 15, 2017

SELL
$167.29 - $191.0 $204,093 - $233,020
-1,220 Reduced 9.05%
12,257 $2.29 Million
Q2 2017

Aug 15, 2017

BUY
N/A
13,477
13,477 $2.32 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $167B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Martin & CO Inc Portfolio

Follow Martin & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martin & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Martin & CO Inc with notifications on news.